urinary urgency, urinarinary incontinence, over active bladder symptoms
Conditions
Interventions
Start of mirabegron
Second urodynamic investigation
Voluntary questionnaire about sexual function
Sponsors
P. Groenendijk, Medisch Centrum Haaglanden, den haag
Eligibility
Inclusion criteria
Inclusion criteria: Female patients, above age of 18, mentally fit to consent and indication for treatment with Mirabegron. Bothersome OAB symptoms. Voiding diary volume urine less then 2200ml. • Signed informed consent • May have had –unsatisfying- treatment with antimuscarinergic medication • Willing to stop medication for lower urinary tract dysfunction 2 days before urodynamic investigation (at entry of study) • Willing to start B3AA (mirabegron)
Exclusion criteria
Exclusion criteria: • Contraindications for the use of Mirabegron (severely impaired kidney- or liver function) • Sediment + or clinical signs of UTI at the start of the urodynamic investigation • Necessity to perform CIC or significant post void residual (>100mL). • Significant voiding abnormalities; bladder outlet obstruction (UDI >grade 1 or BOOI >20) or underactive or acontractile detrusor. • Unwilling or unable – according to treating physician- to stop current treatment for lower urinary tract dysfunction. • Treatment with intradetrusor botulinum toxin less than one year before urodynamic investigation (whether or not symptomatically effective)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of mirabegron on urethral pressure variations | — |
Secondary
| Measure | Time frame |
|---|---|
| • Difference of total number of urethral pressure variations on urodynamic investigation after treatment, compared to initial urodynamic investigation. • Difference in volume to first detrusor contraction between ‘before’ and ‘on treatment’. • Differences in volume to first sensation of filling, normal desire to void and strong desire to void, between ‘before’ and ‘on treatment’. • Difference in volume to first urethral pressure drop between ‘before’ and ‘on treatment’. • Difference in largest pressure drop (cmH2O) between ‘before’ and ‘on treatment’. • To explore the association of symptoms and voiding diary data before and on treatment with a beta 3 adrenoreceptor agonist with significant urethral pressure variations/ urethral pressure drops during urodynamic investigation (before and on treatment). • Sexual function as measured with a questionnaire before and on treatment with beta 3 adrenoreceptor agonist. Comparison of (grouped average) individual before and on treatment effect(s) of a beta 3 adrenoreceptor agonist on symptoms and voiding diary and urodynamic parameters | — |
Contacts
Public ContactP. Groenendijk
Urologist MCH
Outcome results
None listed